Clinical usefulness of free and complexed PSA

Area of Science:

• Urology
• Oncology
• Biochemistry

Background:

• Distinguishing between prostate cancer (CaP) and benign prostatic hyperplasia (BPH) is crucial for patient management.
• Prostate-specific antigen (PSA) is a key biomarker, but its interpretation is complicated by benign conditions.
• The ratio of free PSA to total PSA (% free PSA) has been investigated as a tool to improve diagnostic specificity.

Purpose of the Study:

• To evaluate the efficacy of the free/total PSA ratio in differentiating CaP from BPH patients.
• To assess the impact of physiological variation in PSA levels on diagnostic accuracy.

Main Methods:

• Serum samples were analyzed from 51 CaP patients and 48 BPH patients.
• The ratio of free PSA to total PSA was calculated for all participants.
• Intra-patient variability in PSA levels was assessed by analyzing serial samples drawn within a short timeframe (mean 22 days).

Main Results:

• BPH patients exhibited a significantly higher median % free PSA (16.5%) compared to CaP patients (8.9%).
• CaP patient cancer volumes ranged from 2.0-17.8 mL, while BPH patient prostate volumes ranged from 36.9-313.8 mL.
• Intra-patient variation in PSA levels was found to be approximately 30% within a 22-day period for PSA levels between 4-10 µg/L.

Conclusions:

• The free/total PSA ratio shows potential in distinguishing CaP from BPH, with BPH patients generally having higher ratios.
• Significant physiological variation in PSA levels over short periods can influence the reliability of the % free PSA as a diagnostic marker.
• Further studies are needed to account for PSA variability in clinical decision-making for prostate cancer diagnosis.